Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 2Hematologic Neoplasms 2Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 217fludarabine phosphate 120Rituximab 108Filgrastim 100Peripheral Blood Stem Cell Transplantation 86Etoposide 83fludarabine 80Busulfan 80Radiotherapy 76Tacrolimus 73Methotrexate 73Melphalan 71Mycophenolic Acid 70Cytarabine 65Antilymphocyte Serum 61Whole-Body Irradiation 56Cyclosporine 54Vincristine 49Prednisone 42Doxorubicin 41Methylprednisolone 34Granulocyte Colony-Stimulating Factor 34Dexamethasone 30Cord Blood Stem Cell Transplantation 29sargramostim 27Alemtuzumab 26Stem Cell Transplantation 24Carmustine 24Thiotepa 23thymoglobulin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × CF regimen × Other hematologic neoplasm × Clear all
NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡